5:54 PM
 | 
May 04, 2010
 |  BC Extra  |  Company News

Glenmark, sanofi in pain deal

Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296) partnered with sanofi-aventis Group (Euronext:SAN; NYSE:SNY) to develop and commercialize Glenmark's transient receptor potential vanilloid 3 ( TRPV3; VRL3)...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >